AOD-9604 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-28. Anything still debated is marked as such rather than presented as settled.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
=== Antioxidant activity === Didymin exhibits antioxidant properties by scavenging free radicals and reducing reactive oxygen species (ROS). In neuronal cell studies, it was found to protect cells against hydrogen peroxide-induced oxidative damage, increase cell viability, and stimulate antioxidant defence enzymes including superoxide dismutase, catalase, and glutathione peroxidase. Didymin is among the flavonoids present in orange juice that have been associated with a reduction in markers of oxidative stress and DNA damage.
== Financial assistance == In the Union Budget for 2019–20, the Finance Minister announced ₹804.75 crore (equivalent to ₹10 billion or US$110 million in 2026) to incentivize and promote processing in the fisheries sector for the Financial year 2019–20 through the newly formed Ministry of Fisheries, Animal Husbandry and Dairying. During the Budget speech, the finance minister asserted: "fishing and fishermen communities are closely aligned with farming and are crucial to rural India." The Economic Survey of India for the year 2018–19 had stressed on allied sectors and focused mainly on enhancing rural economy by strengthening Animal husbandry and Fisheries. Apart from this, the government had earlier set aside ₹7,552 crore (equivalent to ₹97 billion or US$1.0 billion in 2026) in the Fisheries and Aquaculture Infrastructure Development Fund (FIDF), which was intended to be utilized in creating both inland and overseas fishery infrastructure in the country. The government had set a target of 20 tonnes for fish production through the Blue Revolution by 2022–23. While announcing the stimulus package in the backdrop of the economic slowdown caused by the recent COVID-19 pandemic in India, the Finance Minister announced ₹20,000 crore (equivalent to ₹260 billion or US$2.7 billion in 2026) outlay to enhance the inland fisheries through Matsya Sampada Yojana.
== As a defensive adaptation == The slime coat of reef fish contains mycosporine-like amino acids (MAAs) which protect the fish from sun damage by absorbing radiation. The greatest number of MAAs is found on the dorsal side of the fish, which is exposed to more radiation. Animals cannot synthesize MAAs, requiring fish to sequester them from their diet. Under water, fish are exposed to a greater number of microorganisms than animals whose skin is exposed mainly to air. In the absence of a stratum corneum, the slime coat serves to protect the fish from attack from harmful microorganisms. This is chiefly done by sloughing off microbes which become trapped in the slime coat, but the slime coat contains antimicrobial peptides and other defensive properties such as lysozyme and C-reactive protein. Parrotfish create extra mucus during sleep which covers their bodies in a cocoon-like structure. It protects them from predators and parasites by masking their scent and providing a physical barrier against them.
=== Research === The molecular mechanisms of chemical toxicity, carcinogen metabolism, and inter-individual genetic variability are the main subjects of Eaton's scientific research. His early research focused on the bioactivation and detoxification pathways of Aflatoxin B1, describing species variations in Cytochrome P450 enzymes (specifically CYP1A2 and CYP3A4) and Glutathione S-transferases (GSTs) to clarify human cancer risks. Additionally, he studied glutathione production and GST-mediated detoxification of pesticides, contaminants, and medicinal substances in Phase II biotransformation. Later in his career, Eaton co-authored studies on the use of "organ-on-a-chip" microphysiological systems, such as dual liver-kidney platforms, to assess the toxicity of nanoparticles and organ damage brought on by substances like aristolochic acid.
Mother Eddy deserves a place in the Trinity as much as any member of it. She has organized and made available a healing principle that for two thousand years has never been employed, except as the merest guesswork. She is the benefactor of the age." — Mark Twain, A Biography, by Albert B. Paine, Vol. III, p. 1271."
Sources: en.wikipedia.org
Between 12 and 14 June, Datafolha interviewed another 2,010 people in 112 Brazilian municipalities, and the Lula government received a good or excellent rating from 37% of respondents, regular from 33%, and bad or terrible from 27%. Three percent of respondents did not express an opinion. According to the survey, Lula's third term maintained a good "balance" of approval and regular ratings over five months, surpassing the ratings of the previous governments of Collor, Temer and Bolsonaro, but still being surpassed by the ratings of the first-term governments of FHC and Dilma. Between 15 and 18 June, the Genial/Quaest institute interviewed 2,029 voters over the age of 16, and the survey showed an increase in the rating from 51% to 56% again compared with the survey released in April of that year. That percentage represents those who said that Lula governs the country well, and the decrease from 42% to 40% represents those who said that Lula governs the country badly. From the end of June to the beginning of July, Lula's third government was measured by the newspaper PoderData, with 2,500 respondents from 262 municipalities across the country, ending the first half of the year with a "balance" in approval. Fifty-one percent of respondents rated Lula's administration positively, while 43% disapproved of the administration and 6% did not know how to rate it. The newspaper also asked respondents how they rated Lula governing the country, and in 3 months the percentage for good governance rose by two points (from 39% to 41%).
Acetoxolutamide is a nonsteroidal androgen and selective androgen receptor modulator (SARM) which was described in 2000 and was never developed or marketed for medical use. It was derived from structural modification of the nonsteroidal antiandrogen bicalutamide and the nonsteroidal SARM acetothiolutamide. Acetoxolutamide shows greatly improved pharmacokinetic properties and anabolic and androgenic potency relative to acetothiolutamide in animals. It is the (2R) enantiomer of andarine (also known as acetamidoxolutamide or androxolutamide).
Absorbance Units Full Scale (AUFS) or Absorption Units Full Scale is a unit of absorbance intensity that denotes the output of a spectrophotometer. The acronym AUFS can also be written out as Absorbance Units per Full Scale Deflection. AUFS is an arbitrary unit of the maximum ultraviolet or visible light absorbance intensity measured by a detector. It can be used in chemical analysis to quantify components in a mixture, as each component's integrated peak area corresponds to their relative abundance. AUFS is given as a number ranging from 0 to 1, where a measurement of 1 AUFS indicates an absorbance reading of 1 at full deflection. Analytical chemistry Chromatography Spectroscopy
c7orf26 interacts uniquely with 11 different proteins, according to the Mentha interactome browser. In particular, c7orf26 interacts with the entire family of 'INTS' (Integrator Complex Subunit 1–7). The Integrator Complex associates with the C-terminal domain of RNA polymerase II large subunit. It is involved in the transcription and processing of their transcripts. INTS mediates recruitment of cytoplasmic dynein to the nuclear envelope. Outside of the INTS gene family, c7orf26 interacts with AK5, HDGF, and ASUN. According to Guirato et al. (2018), there may be some evidence that regions on chromosome 7 may be directly linked to a nuclear estrogen receptor (ESR2) that modulates cancer cell proliferation and tumor growth. In another journal article by Fu et al. (2014), there is further indication that regions along chromosome 7, located between open reading frames 20-30, directly correlate to cellular functions of a hepatoma-derived growth factor (HDGF), another way of expressing normal function in tumorigenesis.
Americium-241 often enters landfills from discarded smoke detectors. The rules associated with the disposal of smoke detectors are relaxed in most jurisdictions. In the U.S., the "Radioactive Boy Scout" David Hahn was able to concentrate americium-241 from smoke detectors after managing to buy a hundred of them at remainder prices and also stealing a few. There have been a few cases of exposure to americium-241, the worst being Harold McCluskey who, at age 64, was exposed to 500 times the occupational standard for americium-241 as a result of an explosion in his lab. McCluskey died at age 75, not as a result of exposure, but of a heart disease which he had before the accident. Americium-241 has also been detected in the oceans as a result of nuclear testing conducted by various nations.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.